Royal Bank of Canada
MIRM icon

Royal Bank of Canada’s Mirum Pharmaceuticals MIRM Stock Holding History

Royal Bank of Canada’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81M Buy
32,518
+12,361
+61% +$1.24M ﹤0.01% 2818
2026
Q1 		$1.86M Sell
20,157
-15
-0.1% -$1.41K ﹤0.01% 3144
2025
Q4 		$1.59M Buy
20,172
+4,912
+32% +$353K ﹤0.01% 3293
2025
Q3 		$1.12M Buy
15,260
+8,654
+131% +$550K ﹤0.01% 3900
2025
Q2 		$337K Sell
6,606
-353
-5% -$15.7K ﹤0.01% 4763
2025
Q1 		$312K Sell
6,959
-3,550
-34% -$167K ﹤0.01% 4359
2024
Q4 		$434K Sell
10,509
-16,707
-61% -$696K ﹤0.01% 4185
2024
Q3 		$1.06M Buy
27,216
+22,392
+464% +$893K ﹤0.01% 3497
2024
Q2 		$165K Buy
4,824
+2,528
+110% +$66.3K ﹤0.01% 4910
2024
Q1 		$58K Sell
2,296
-5,551
-71% -$153K ﹤0.01% 5469
2023
Q4 		$232K Buy
7,847
+4,357
+125% +$132K ﹤0.01% 4976
2023
Q3 		$110K Buy
3,490
+1,639
+89% +$44.9K ﹤0.01% 5322
2023
Q2 		$48K Buy
1,851
+530
+40% +$14.1K ﹤0.01% 5802
2023
Q1 		$32K Sell
1,321
-1,413
-52% -$32.2K ﹤0.01% 5839
2022
Q4 		$53K Buy
2,734
+2,387
+688% +$47.2K ﹤0.01% 5839
2022
Q3 		$7K Buy
347
+139
+67% +$3.35K ﹤0.01% 6598
2022
Q2 		$4K Sell
208
-131
-39% -$3.09K ﹤0.01% 6733
2022
Q1 		$8K Sell
339
-657
-66% -$13.4K ﹤0.01% 7059
2021
Q4 		$15K Buy
996
+695
+231% +$10.8K ﹤0.01% 6914
2021
Q3 		$6K Sell
301
-299
-50% -$4.86K ﹤0.01% 7084
2021
Q2 		$10K Buy
600
+430
+253% +$7.71K ﹤0.01% 6873
2021
Q1 		$3K Buy
+170
New +$3.25K ﹤0.01% 7163
2020
Q4 		– Sell
-14
Closed – – 7200
2020
Q3 		$0 Buy
14
+1
+8% +$21 ﹤0.01% 6810
2020
Q2 		$0 Sell
13
-254
-95% -$4.25K ﹤0.01% 6792
2020
Q1 		$4K Buy
267
+188
+238% +$3.08K ﹤0.01% 6116
2019
Q4 		$2K Sell
79
-20
-20% -$213 ﹤0.01% 6563
2019
Q3 		$1K Buy
+99
New +$1.21K ﹤0.01% 6478

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's MIRM Position: Q2 2026 in Review

Royal Bank of Canada increased its Mirum Pharmaceuticals (MIRM) stake by 61% in Q2 2026, buying an estimated $1.24M and bringing the position to 32,518 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2818.

Royal Bank of Canada first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Royal Bank of Canada held 32,518 shares of Mirum Pharmaceuticals worth $3.81M as of Q2 2026.
  • Royal Bank of Canada bought 12,361 Mirum Pharmaceuticals shares in Q2 2026, an estimated $1.24M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2818 holding.
  • Royal Bank of Canada first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.